With regard to NPM1 and FLT3ITD, several studies have shown that AML with NPM1 mutation, but without FLT3ITD mutation, is associated with significantly better OS and EFS [29–32]; one study demonstrated that NPM1 mutation with or without FLT3ITD was only favorable in achieving complete remission but was associated with a high relapse rate with no OS and EFS benefits [33]. The gene discussed is NPM1; the disease is acute myeloid leukemia.